HGH Fragment 176-191 vs IGF-1 LR3

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

HGH Fragment 176-191

HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.

Full details →

IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.

Full details →

Side-by-Side Comparison

AspectHGH Fragment 176-191IGF-1 LR3
MechanismMimics the lipolytic region of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without affecting blood sugar or promoting growth. Works independently of GH receptors.Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours.
Typical DosageTypical dosing: 250-500mcg daily, often split into 2-3 doses. Usually administered on empty stomach, often with fasted cardio.Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles.
AdministrationSubcutaneous injection. Best results when used fasted and combined with exercise. Avoid eating for 30 minutes post-injection.Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off.
Side EffectsGenerally well-tolerated. May cause injection site irritation, temporary lethargy, or headache. Does not affect blood glucose significantly.Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions.
Best For

What They Have in Common

Both HGH Fragment 176-191 and IGF-1 LR3 are commonly used for:

Key Differences

Ready to Learn More?